A newborn's immune defenses continue developing after birth, leaving the earliest days of life particularly important for protection against infection.

New research published in Science Translational Medicine on October 7, 2026, identifies a protective pathway through which early gut microbes may help newborns resist dangerous bacterial infections.

How the First Gut Microbes Influence Immunity

The gut microbiota is the community of bacteria and other microorganisms living in the digestive tract. Its early development helps shape interactions between microbes and the cells responsible for maintaining intestinal health. In the new study, researchers found that newborn mice produced substantial amounts of calprotectin, an antimicrobial protein complex, in their intestines.

Unlike the pattern commonly observed in adults, where certain immune cells are a major source, the protein in newborn mice was produced predominantly by intestinal epithelial cells, which form the lining of the gut. This discovery suggests that the intestinal lining does more than separate the digestive tract from its surroundings. During early development, its cells can actively produce protective substances that help limit harmful bacterial growth.

When researchers disrupted the early establishment of beneficial microbes or prevented calprotectin production, newborn mice became more vulnerable to serious bacterial infections. The results point to an important relationship between early microbial exposure and the development of natural protective defenses.

The Biological Pathway Behind the Protection

The researchers identified Lactobacillus bacteria as contributors to this process. Certain early-colonizing bacteria produce indole-3-lactic acid (ILA), a compound generated during microbial metabolism. ILA activates the aryl hydrocarbon receptor, commonly known as AhR, in intestinal epithelial cells. This cellular signaling pathway encourages the production of calprotectin, helping establish an antimicrobial defense during a particularly vulnerable stage of development.

Experiments involving genetically modified mice supported the importance of this mechanism. Animals unable to produce sufficient calprotectin in their intestinal lining showed increased susceptibility to infection. Researchers also found that disrupting the early microbial community with antibiotics reduced beneficial bacteria and lowered calprotectin levels.

The results suggest that the relationship between beneficial microbes and intestinal cells is not simply a matter of which bacteria are present. The chemical signals produced by those bacteria may also determine whether important protective processes become activated.

Expert Insight

The research was led by Shikha Negi and colleagues and published in Science Translational Medicine. The authors summarized their findings in the study's scientific abstract with the following exact statement: “Thus, microbiota-epithelial dynamics that occur at birth are essential for programming early-life immunity and suggest that probiotic approaches targeting epithelial cells could prevent neonatal sepsis and death.”

What Antibiotic Exposure Reveals

Antibiotics are essential for treating many serious bacterial infections, including infections affecting newborns. However, these medicines can also reduce populations of beneficial bacteria, potentially altering the microbial signals involved in early immune development.

In the study, antibiotic-exposed newborn mice showed reduced levels of beneficial Lactobacillus and lower calprotectin production. This was associated with weaker protection against infection. The findings offer a possible explanation for how changes in the early gut microbiota may affect particular immune defenses. Nevertheless, the results do not mean that necessary antibiotic treatment should be avoided or delayed.

Could the Discovery Lead to New Treatments?

To investigate whether the same pathway might operate in humans, researchers examined miniature intestinal tissues grown in the laboratory from human tissue samples. Known as intestinal organoids, these models allow scientists to study cellular behavior under controlled conditions.

The experiments indicated that infant stool samples, Lactobacillus, and ILA could stimulate calprotectin production in human intestinal cells through the AhR pathway. These observations provide supporting evidence that the biological mechanism may be relevant to human intestinal development.

Potential future treatments could involve carefully selected beneficial bacteria, microbial metabolites, or approaches designed to activate protective responses in intestinal cells. Such strategies might eventually complement established methods for preventing and treating neonatal infections.

The latest research reveals a potential mechanism through which early gut microbes help establish newborn immune defenses. In experiments involving mice, beneficial bacteria and their metabolic product ILA activated a cellular pathway that increased calprotectin production in the intestinal lining, improving protection against dangerous infections.

Human intestinal tissue models provided additional evidence that a similar process may occur in people. Although the findings could inspire new approaches to neonatal infection prevention, they do not yet establish a proven treatment. Further clinical research will be essential to determine how this natural defense mechanism can be translated into safe and effective care for newborns.